admin

About Ole Frølich

This author has not yet filled in any details.
So far Ole Frølich has created 27 blog entries.

Pharming Reports On Financial Results For Q1 2015

2017-05-31T19:25:13+00:00

Pharming Group N.V. has published its (unaudited) financial report for Q1 2015 ended 31 March 2015. From the financial highlights: Ruconest sales in the US amounted to 0.6 million EUR and sales by Sobi in the EU amounted to 0.4 million EUR. Alongside Pharming realised initial direct sales in Austria, Germany and the Netherlands. Product [...]

Dyax Corp. Announces First Quarter 2015 Financial Results

2017-05-31T19:25:13+00:00

Dyax Corp. has announced financial results for the first quarter ended March 31, 2015. Recent highlights include: Reported positive safety, pharmacokinetic, biomarker and proof-of-concept efficacy results from the Phase 1b study of DX-2930 in HAE patients; Receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for [...]

New and Convenient Vial Size of Berinert Accepted by Several European Health Authorities

2015-05-14T16:27:14+00:00

Several European health authorities have completed the assessment of a new, low-volume presentation size for the existing indications of Berinert, a human plasma-derived, pasteurized, and nanofiltered C1-esterase inhibitor (C1-INH) concentrate from CSL Behring. It is indicated for the treatment and pre-procedure prevention of acute episodes of HAE type I and II. "This new vial size [...]

Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930

2017-05-31T19:25:13+00:00

Dyax Corp. has announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of HAE attacks. The ongoing Phase 1b study is a multi-center, randomized, double-blind, placebo-controlled, [...]

New hae day :-) website

2017-05-31T19:25:13+00:00

Today HAEi has launched a new hae day :-) website - a forum dedicated to the global HAE awareness day. Among many other things the website contains a number of case stories, shared by patients in order to help raise awareness of the effects of HAE on the everyday lives of people around the world. [...]

Nominations to Pharming’s Board Of Supervisory Directors

2015-04-07T13:18:02+00:00

Pharming Group N.V. has nominated Paul Jai Sekhri and Jan Hendrik Egberts as members of the Board of Supervisory Directors. The nominations will be subject to shareholders’ approval at the upcoming Annual General Meeting of Shareholders, which will take place on 30 April 2015. Mr. Sekhri (1958) has over 28 years of operational experience in [...]

OPuS-2 study now enrolling patients

2015-04-07T13:21:01+00:00

OPuS-2 is an 12 week study of BCX4161, an oral kallikrein inhibitor being studied for prevention of HAE attacks in patients with Type I and II HAE. This study is currently open to enrolling patients in the US, UK, and Germany, with planned clinical trial locations in Belgium, Canada, Hungary, Italy and France. If you [...]

Pharming Reports On Preliminary Financial Results 2014

2017-05-31T19:25:13+00:00

Pharming Group N.V. has published its preliminary (unaudited) financial results for the year ended 31 December 2014. From the financial highlights: Revenues from operations increased to 21.2 million EUR (2013: 6.8 million EUR) as a result of higher license fees, including the receipt of a 20.0 million USD (16 million EUR) milestone from US partner [...]